Jeena Sikho Lifecare Limited has announced a significant business development with its empanelment with Air India for providing specialized healthcare services. The company informed the stock exchanges on December 26, 2025, about this strategic partnership that expands its service reach to Air India's workforce and eligible beneficiaries.

Empanelment Details and Service Authorization

The empanelment authorizes Jeena Sikho Lifecare Limited's Ayurveda Panchkarma hospitals to provide cashless treatment services to Air India employees and their eligible beneficiaries. This arrangement allows the company to offer its specialized Ayurveda Panchkarma treatments directly through Air India's healthcare network, following applicable terms and conditions established between the parties.

Hospital Network Coverage

The empanelment covers nine hospital locations across three states, providing comprehensive geographical coverage for Air India's beneficiaries:

Regulatory Compliance and Business Nature

The company has confirmed that this empanelment arrangement operates within the ordinary course of business and maintains full regulatory compliance. Key compliance aspects include:

• No related party transactions are involved in this arrangement
• The partnership does not fall under material contracts requiring disclosure beyond Regulation 30 of SEBI (LODR) Regulations, 2015
• All applicable terms and conditions for service delivery have been established
• The arrangement aligns with the company's existing business operations in Ayurveda Panchkarma treatments

Strategic Business Impact

This empanelment represents an expansion of Jeena Sikho Lifecare Limited's institutional healthcare partnerships, adding Air India to its network of corporate clients. The cashless treatment facility enhances accessibility for Air India employees and beneficiaries seeking Ayurveda Panchkarma treatments across the company's hospital network. The partnership leverages the company's existing infrastructure of 120 Ayurveda clinics and hospitals, focusing on its specialized Panchkarma treatment services.

The company has indicated it will continue to provide updates and relevant correspondence regarding this partnership as necessary, ensuring transparent communication with stakeholders about this business development.

Jeena Sikho Lifecare Limited's Board of Directors conducted a meeting on December 23, 2025, at the company's registered office in Mohali, Punjab, to address significant changes in its internal audit structure. The board meeting, which commenced at 7:00 PM and concluded at 7:15 PM, focused on the transition of internal audit responsibilities.

Internal Auditor Resignation

The board formally accepted the resignation of M/s Deepak K Garg Associates, Chartered Accountants, from their position as Internal Auditor. The resignation was submitted via email on December 23, 2025, with the auditor citing pre-occupation with other professional commitments as the primary reason for stepping down.

The internal auditor confirmed that there were no material reasons for resignation other than those mentioned in the resignation communication. CA. Puneet Gupta, representing the firm, expressed gratitude for the opportunity and cooperation received during the tenure.

New Internal Auditor Appointment

Simultaneously, the board approved the appointment of M/s. Forvis Mazars LLP as the new Internal Auditor for the Financial Year 2025-26. The appointment ensures continuity in the company's internal audit processes and compliance requirements.

M/s. Forvis Mazars LLP is described as a leading international assurance, tax, and advisory firm that assists clients in achieving sustainable and responsible growth. The firm serves a wide range of industries with strong sector-specific understanding and offers a diverse portfolio of services that enhances the relevance and quality of its offerings.

Regulatory Compliance

The board meeting outcomes were communicated to both the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed annexures containing additional disclosures as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The transition reflects the company's commitment to maintaining robust internal audit practices while ensuring compliance with regulatory requirements. The appointment of an established international firm demonstrates the company's focus on strengthening its governance framework for the upcoming financial year.